BRN-103
BRN-103 is a nicotinamide derivative and an inhibitor of the VEGF/VEGFR2 angiogenesis signaling pathway. BRN-103 concentration-dependently inhibits VEGF-induced migration, proliferation and capillary-like tube formation of HUVECs, and suppresses microvascular sprouting of ex vivo aortic rings. BRN-103 inhibits VEGF-induced phosphorylation of VEGFR2 Tyr1175, as well as the downstream phosphorylation of AKT Ser473 and eNOS Ser1172, while exerting a weak inhibitory effect on ERK phosphorylation. BRN-103 can be used in studies related to VEGF/VEGFR2 signaling and angiogenesis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1346265-80-2
- 分子式: C24H25ClN4O
- 分子量:420.94
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
VEGFR アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
VEGFR2 |
体外実験
BRN-103 (0.1-10 μM; 24 h) inhibits VEGF-induced migration of human umbilical vein endothelial cells in Transwell assays in a dose-dependent manner[1].
BRN-103 (0.1-1 μM; 1 h pre-incubation, 24 h incubation with VEGF) inhibits VEGF-induced scratch wound healing migration of human umbilical vein endothelial cells in a dose-dependent manner[1].
BRN-103 (0.1-1 μM) inhibits VEGF-induced proliferation of human umbilical vein endothelial cells (HUVECs) in a dose-dependent manner[1].
BRN-103 (0.1-1 μM) dose-dependently inhibits VEGF-induced capillary-like tube formation in human umbilical vein endothelial cells[1].
BRN-103 (0.1-1 μM; 1 h pre-incubation, 5 min incubation with VEGFR2) dose-dependently inhibits VEGF-induced phosphorylation of VEGFR2 (Tyr-1175) in human umbilical vein endothelial cells[1].
BRN-103 (0.1-1 μM; 1 h pre-incubation, followed by 5 min, 30 min, or 1 h of incubation with VEGF) dose-dependently inhibits VEGF-induced phosphorylation of AKT (Ser-473) and eNOS (Ser-1172), and slightly inhibits phosphorylation of ERK (Thr-202/Tyr-204) in human umbilical vein endothelial cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human umbilical vein endothelial cells (HUVECs)
-
Concentration:0.1 μM, 0.5 μM, 1 μM
-
Incubation Time:1 h pre-incubation; 5 min incubation with VEGF
-
Result:Dose-dependently suppressed VEGF-induced phosphorylation of VEGFR2 at Tyr-1175 in HUVECs, with greater inhibition observed at higher concentrations.
-
Cell Line:human umbilical vein endothelial cells (HUVECs)
-
Concentration:0.1 μM, 0.5 μM, 1 μM
-
Incubation Time:1 h pre-incubation; 5 min (p-ERK), 30 min (p-AKT), 1 h (p-eNOS) incubation with VEGF
-
Result:Significantly and concentration-dependently suppressed VEGF-triggered phosphorylations of AKT (Ser-473) and eNOS (Ser-1172) in HUVECs.
Mildly inhibited VEGF-induced phosphorylation of ERK (Thr-202/Tyr-204) in HUVECs.
化学情報
-
CAS 番号 1346265-80-2
-
分子量 420.94
-
分子式 C24H25ClN4O
-
SMILES
O=C(NC=1C=CC=C(Cl)C1)C2=CC=CN=C2NC3CCN(CC=4C=CC=CC4)CC3
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
BRN-103 関連分類
HY-18198 関連分類
Powered by Bioz